BioCentury
ARTICLE | Clinical News

Ascentage reports Phase I data for APG-1252 in solid tumors

June 1, 2018 6:11 PM UTC

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) reported interim data from 13 evaluable patients with solid tumors, including six with small cell lung cancer (SCLC), in a Phase I trial showing that APG-1252 led to one confirmed partial response in a patient with metastatic NSCLC. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

Patients in the open-label, U.S. trial received twice-weekly 10-400 mg doses of IV APG-1252. APG-1252 was well tolerated with no adverse events leading to treatment discontinuation or hematological toxicity reported. The maximum tolerated dose (MTD) has not yet been reached...